The Relationship Between Osteoarthritis and Sarcopenia in Geriatric Diabetic Patients

Sema Basat,1 Ridvan Sivritepe,2 Damla Ortaboz,3 Ecem Sevim,4 Sabri Atay,5 Arzu Baygul6

1Department of Internal Medicine, University of Health Sciences Turkey, Umraniye Training and Research Hospital, Istanbul, Turkey
2Department of Internal Medicine, Istanbul Beykoz State Hospital, Istanbul, Turkey
3Department of Internal Medicine, Istanbul Arnavutköy State Hospital, Istanbul, Turkey
4Division of Rheumatology, Hospital for Special Surgery, New York, USA
5Antalya Korkuteli Health Directorate, Antalya, Turkey
6Department of Biostatistics, Koç University Faculty of Medicine, Istanbul, Turkey

Abstract

Objectives: Osteoarthritis is a common disease affecting the quality of life in the elderly population. Osteoarthritis is a painful condition commonly encountered in patients aged 65 years and older and it may cause muscle weakness. Sarcopenia is a condition that has an increasing prevalence in the elderly population. The present study evaluated the relationship between sarcopenia and osteoarthritis.

Methods: The study included 100 patients aged 65 years and older who were diagnosed with diabetes mellitus. The patients were divided into two groups as Group 1 and Group 2. Group 1 was composed of 50 patients with diabetes and osteoarthritis and Group 2 was composed of 50 patients with diabetes but without osteoarthritis. A detailed medical history was obtained from all patients and all patients underwent physical examination. The get-up and go test was performed, handgrip strength was measured with a hand dynamometer, bioimpedance analysis was performed, and mid-upper arm circumference, calf circumference and waist circumference were measured, and laboratory tests including complete blood count, biochemical nutritional parameters, liver and kidney function tests, and erythrocyte sedimentation rate were ordered. The Kellgren and Lawrence grading system was used to evaluate the severity of osteoarthritis and the skeletal muscle mass index was used to evaluate the muscle mass. These parameters were compared between the two groups.

Results: Of the study participants, 1% had severe sarcopenia, 22% had moderate sarcopenia, and 77% did not have sarcopenia. Albumin (p=0.013), magnesium (p=0.038), total protein (0.004), erythrocyte sedimentation rate (p=0.047), hemoglobin level (p=0.018), muscle strength (p=0.046), height (p=0.033), and muscle mass (p<0.05) were significantly different in patients with osteoarthritis compared to patients without osteoarthritis. Patients with osteoarthritis achieved poorer results on the get-up and go test (p=0.014), and mid-upper arm circumference (p=0.028), and calf circumference (p=0.016) were lower in this group. There was a negative moderate correlation between the muscle mass and the Kellgren and Lawrence grade (p<0.05, r: −0.405), whereas there was a positive moderate correlation between sarcopenia index and the Kellgren and Lawrence grade (p<0.05, r: 0.320) in patients with osteoarthritis.

Conclusion: The present study is the first to evaluate the relationship between sarcopenia and osteoarthritis in geriatric patients with type II diabetes mellitus. The authors suggest that pain associated with osteoarthritis results in immobility, decrease in functional performance, and thus development of sarcopenia.

Keywords: Geriatrics; osteoarthritis; sarcopenia; type II diabetes mellitus.

Please cite this article as “Basat S, Sivritepe R, Ortaboz D, Sevim E, Atay S, Baygul A. The Relationship Between Osteoarthritis and Sarcopenia in Geriatric Diabetic Patients. Med Bull Sisli Etfal Hosp 2021;55(4):516–523.”
Diabetes mellitus is an important public health problem in Turkey as well as in the world. Diabetes mellitus and impaired glucose intolerance are considered to be related with aging and their prevalence rates increase with increasing age. There are two main polygenic defects in type II diabetes mellitus. These include insulin resistance and impairment in beta-cell insulin secretion. Insulin resistance plays a role in the pathophysiology of hypertension, hyperlipidemia, and obesity, and it is also thought to be involved in the development of sarcopenia. Sarcopenia, which is defined as the progressive generalized loss of muscle mass and muscle strength, is one of the most important causes of frailty, disability, and morbidity in the elderly population. Sarcopenia and associated disorders pose a significant burden on the patients and their relatives as well as on the health-care systems and economies of the countries. Several mechanisms are implicated in the onset and progression of sarcopenia. These mechanisms may be related to protein synthesis, proteolysis, neuromuscular integrity, and muscle fat content. Various mechanisms can be involved in sarcopenic individuals and their relative contribution may vary over time. The pathophysiology of sarcopenia related with aging can be explained by a decrease in anabolic hormones (testosterone, estrogen, growth hormone, and insulin-like growth factor-1 [IGF-1]), increase in apoptotic activity of myofibrils, increase in proinflammatory cytokines (tumor necrosis factor-alpha [TNF-α] and interleukin [IL]-6), increased oxidative stress associated with free radical accumulation, alterations in mitochondrial functions of myocytes, and decrease in the number of α-motor neurons. Chronic disorders as osteoarthritis are catabolic processes contributing to the progression of sarcopenia. Considering the fact that common factors could affect changes in the different components of the musculoskeletal system, it is possible that osteoarthritis could predict age-related sarcopenia. Osteoarthritis is the most common joint disorder occurring in patients aged 65 years and older at a rate of 40% and affecting the knee joint. It is difficult to suggest a clear relationship between osteoarthritis and diabetes; however, many studies have demonstrated a positive relationship between these two entities. Several authors have suggested that the prevalence of osteoarthritis is higher in young and middle-aged diabetic patients, and joint destruction starts at an earlier age and shows a more severe course than in the control group. It was demonstrated that insulin resistance and hyperinsulinemia stimulates bone growth in patients with type II diabetes mellitus.

Multiple mechanisms are involved in the pathogenesis of sarcopenia and osteoarthritis both of which have an increasing prevalence among the middle-aged and elderly diabetic population and are associated with a decline in physical function and decrease in the quality of life. These two conditions also constitute an important public health concern due to treatment costs, associated complications and increasing prevalence in recent years in Turkey as well as in the world. The aim of the present study was to evaluate the relationship between sarcopenia and osteoarthritis, which is one of the musculoskeletal disorders responsible for severe disability that occurs with aging in diabetic patients.

Methods

The study was designed as a cross-sectional study and has been approved by the local ethics committee. (The Ethics Committee of University of Health Sciences Umranliye Traning and Research University Hospital, Date: 22.01,2016; Number: 1154) The study included 100 consecutive patients aged 65 years and older who were admitted to the diabetes outpatient clinics at our hospital. The patients were divided into two groups. Group 1 was composed of diabetic patients who presented with joint pain and were diagnosed with osteoarthritis and who did not have any other conditions that would cause sarcopenia. Group 2 was composed of diabetic patients who did not have joint pain and in whom the diagnosis of osteoarthritis was ruled out. Patients with type I diabetes mellitus, patients with a history of major surgery, malignancy, severe cardiovascular disease, acute cerebrovascular conditions, acute or chronic infections, uncontrolled diabetes, major psychiatric condition, patients with abnormal kidney and liver function tests, patients with a pacemaker or any type of implant, severe edema, severe electrolyte disturbances, patients with any condition that would affect mobility (cerebrovascular accident, end-stage dementia, hip dislocation, extremity injury caused by traffic accident, etc.), and patients with diabetic neuropathy or polyneuropathy and those with additional chronic conditions that would cause sarcopenia were excluded from the study. Weight, height, body mass index, waist circumference, and blood pressure of the patients were measured. The get-up and go test was performed, handgrip strength was measured with a hand dynamometer, bioimpedance analysis (BIA) was performed, and mid-upper arm circumference, calf circumference and waist circumference were measured. Laboratory tests including complete blood count, biochemical nutritional parameters, liver and kidney function tests, and erythrocyte sedimentation rate were ordered. Fasting blood samples were collected in the morning between 08:00 AM and 10:00 AM. Blood samples were collected into SST II, LH PST II, and EDTA tubes, and simultaneously analyzed. Handgrip strength was measured using a hand dynamometer. Anthropometric measurements including height, mid-upper arm circumference, and calf circumference were obtained.
The Kellgren and Lawrence grade and skeletal muscle mass index (SMMI) were calculated and these values were compared between the two groups.

**Metabolic Parameters**

Plasma glucose was measured with an enzymatic test, glycated hemoglobin was measured using high-performance liquid chromatography (HPLC) method. Total cholesterol, high-density lipoprotein, low-density lipoprotein, calcium, phosphor, alanine transaminase, aspartate transaminase, gamma-glutamyl transferase, alkaline phosphatase, amylase, and albumin, and triglyceride concentrations were measured using enzymatic colorimetric test. Creatinine level was measured with Jaffe reaction, Vitamin D level was measured using HPLC method, bilirubin levels were measured using the diazo reaction. C-reactive protein level was measured using enzyme immunoassay, iron, iron binding capacity, magnesium, total protein, uric acid, and blood urea nitrogen were measured using spectrophotometry, ferritin level was measured using immunochemical measurement, and folate level was measured using radioimmunoassay. Potassium, sodium, and chloride levels were measured by ion-selective electrode, creatine kinase and lactic dehydrogenase activity were measured by kinetic analysis method. Lipase levels were measured by turbidimetric method, erythrocyte sedimentation rate was measured by the Westergren method. TSH, free T3, free T4 and Vitamin B12 levels were measured by electrochemiluminescence, and hemogram parameters were measured by flow cytometry.

**Anthropometric Measurements**

Height was measured using a stadiometer (Ekoter mechanical stadiometer with scale), while the shoes, socks, and hats were removed. Weight was measured using a daily-calibrated electronic scale (Ekoter mechanical stadiometer with scale), while the shoes, socks, and heavy garments were removed. The body mass index (BMI; kg/m²) was calculated using these measurements. The mid-upper arm circumference and calf circumference were measured using a tape. A mid-upper arm circumference <22 cm was considered low and a value above 22 cm was considered normal; a calf circumference <31 cm was considered low; and a value above 31 cm was considered normal.[16]

**Assessment of Osteoarthritis**

Knee osteoarthritis was assessed by a standing semiflexed anterior-posterior radiograph as per the Altman atlas.[17] Each radiograph was assessed by the common opinion of three assessors as per the Altman atlas. The Kellgren and Lawrence grading system was used to evaluate the severity of osteoarthritis.[18] The patient were divided into five groups as the following: Grade 0 = Normal, Grade 1 = suspected, possible joint space narrowing and subtle osteophytes, Grade 2 = mild, definite osteophytes and possible joint space narrowing, Grade 3 = moderate, multiple moderate osteophytes, definite joint space narrowing, some sclerosis, and possible epiphyseal deformity, and Grade 4 = severe, large osteophytes, gross loss of joint space, marked sclerosis, and definite epiphyseal deformity.

**Definition of Sarcopenia**

The SMMI was calculated using weight, muscle mass (%), and BIA with the following formula: SMMI (kg) = ([height²/ resistance × 0.401] + [gender × 3.825] + [age × −0.071]) + 5.102. Height was measured in centimeters, resistance was measured in Ohm, 1 point was assigned to male gender and 0 points was assigned to female gender, and age was evaluated in years. The cutoff values for SMMI in males are as follows: ≥10.76 kg/m², normal; 8.51–10.75 kg/m², moderate sarcopenia: ≤8.50 kg/m², and severe sarcopenia.[19,20]

**Handgrip Strength**

The right and left handgrip strength was measured using a hydraulic hand dynamometer (JAMAR hydraulic hand dynamometer, Sammons Preston). Handgrip strength in both sides was measured three times while the patient was in seated position with the arm positioned next to the trunk and the elbow flexed at 90°, and the average of three measurements was recorded.[21]

**Physical Performance**

The physical performance was evaluated with the get-up and go test. The patients were instructed to stand up from a chair without holding the armrests, walk 3 m and turn around, walk back to the chair, and then sit down. The performance score was evaluated as follows: 1 = normal, 2 = subtly abnormal, 3 = mildly abnormal, 4 = moderately abnormal, and 5 = severely abnormal. The score of patients showing no evidence for the risk of falls during the test was considered to be normal and the score of patients showing any evidence for the risk of falls during the test was considered to be severely abnormal.[22]

**Statistical Analysis**

Descriptive statistics (mean, standard deviation, minimum, median, and maximum) were used to define continuous variables. The Student’s t-test was used to compare two independent variables with normal distribution, and the Mann–Whitney U test was used to compare two variables without normal distribution. Pearson's correlation coefficient was used to evaluate the relationship between two variables with normal distribution, and Spearman's rho cor-
relation coefficient was calculated to evaluate the relationship between two variables without normal distribution. Chi-square test was used (Fisher’s Exact test, where appropriate) to evaluate the relationship between categorical variables. The level of statistical significance was set at 0.05. The statistical analysis was performed using MedCalc Statistical Software 12.7.7 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2013).

**Results**

Of 100 patients included in the study, 35 were male and 65 were female. The mean age was 71.3 + 5.3 years. When patients were categorized according to the sarcopenia classification system proposed by the European Working Group on Sarcopenia in Older People (EWGSOP), 1% had severe sarcopenia, 22% had moderate sarcopenia, and 77% did not have sarcopenia. Demographic data, anthropometric measurements, and clinical and biochemical parameters are summarized in Table 1.

There were significant differences between patients with and without osteoarthritis in terms of albumin (p=0.013), magnesium (p=0.038), total protein (p=0.004), ESR (p=0.047), hemoglobin level (p=0.018), muscle strength (p=0.046), height (p=0.033), and muscle mass (p<0.05). Patients with osteoarthritis achieved significantly worse scores in the get-up and go test (p=0.014), and mid-upper arm circumference (p=0.028) and calf circumference (p=0.016) were lower. In patients with osteoarthritis, there was a moderate negative correlation between the muscle mass and the Kellgren and Lawrence grade (p<0.01, r: −0.405), and there was a moderate positive correlation between the SMMI and the Kellgren and Lawrence grade (p<0.05, r: 0.320) (Table 2).

There was significant difference between patients with moderate sarcopenia and non-sarcopenic patients in terms of amylase (p=0.013), iron (p=0.028), potassium (p=0.007), protein (p=0.043), ESR (p<0.05), hemoglobin (p<0.05), handgrip strength (p<0.05), height (p<0.05), muscle mass (p<0.05), gender (p<0.05), the get-up and go test (p<0.05), Kellgren and Lawrence grade (p=0.020), and BMI (p<0.05) (Table 3).

**Discussion**

To the best of our knowledge, this is the first study to evaluate the association between sarcopenia and osteoarthritis in geriatric diabetic patients. The term sarcopenia (in Greek, sarx for flex and penia for loss) has been proposed to describe the loss of muscle strength associated with decreased muscle mass, decline in muscle functions and aging, and it is a complex syndrome resulting in disability and dependence with the progression of disease.[23,24] Sarcopenia, which is defined as a relatively new geriatric syndrome, has become a significant burden on the healthcare systems particularly in the developed countries due to increasing prevalence in the elderly population.[8,25,26] In the literature, the prevalence of sarcopenia in women aged 50 years or older was reported to be ranging between 1% and 30%. [27] Sarcopenia has a complex pathophysiology in the elderly.

| Table 1. Demographic data, anthropometric measurements, and clinical parameters |
|--------------------------|--------------------------|
| **N** | **%** |
| Sarcopenia | | |
| Serious | 1 | 1 |
| Intermediate | 22 | 22 |
| No sarcopenia | 77 | 77 |
| Get up and go test | | |
| Normal | 38 | 38 |
| Very light normal | 34 | 34 |
| Slightly normal | 21 | 21 |
| Moderately abnormal | 5 | 5 |
| Severely abnormal | 1 | 1 |
| Upper arm circumference (cm) | | |
| Bad | 12 | 12 |
| Good | 88 | 88 |
| Calf circumference (cm) | | |
| Bad | 23 | 23 |
| Good | 77 | 77 |
| Hand dynamometer (kg) | | |
| Bad | 55 | 55 |
| Good | 45 | 45 |
| Osteoarthritis | | |
| Yes | 50 | 50 |
| No | 50 | 50 |
| Kellgren lawrence | | |
| Stage 0 | 48 | 48.5 |
| Stage 1 | 18 | 18.2 |
| Stage 2 | 19 | 19.2 |
| Stage 3 | 10 | 10.1 |
| Stage 4 | 4 | 4 |

| Table 2. The correlation between the SMMI/Muscle Mass and the Kellgren-Lawrence grade |
|--------------------------|--------------------------|
| **Osteoarthritis** | **Kellgren Lawrence** |
| Muscle mass | | |
| Yes | −0.405* |
| No | 0.088 |
| SMMI* | | |
| Yes | 0.320* |
| No | −0.007 |

*SMMI: Skeletal muscle mass index.*
Both intrinsic and extrinsic factors have been implicated in the development of sarcopenia. Intrinsic factors include decrease in anabolic hormones (testosterone, estrogen, growth hormone, and IGF-1), increased apoptotic activity in the myofibrils, increased levels of proinflammatory cytokines (particularly TNF-α and IL-6), oxidative stress associated with the accumulation of free radicals, changes in mitochondrial functions in the myocytes, and decrease in the number of α-motor neurons, whereas extrinsic factors include energy deficiency, decreased protein intake, and immobility. On the other hand, the presence of acute and chronic diseases can also contribute to the development of sarcopenia in the elderly individuals. Osteoarthritis is an important and common disease resulting in morbidity and mortality. There are limited data regarding the prevalence of osteoarthritis in the population. It has long been known that there is a relationship between chronic diseases and impaired life quality and increased risk of mortality and morbidity.

The present study found a significant association between osteoarthritis and sarcopenia. Recent studies have shown that osteoarthritis in the knee and hip joint in the elderly people results in a decrease in the muscle mass and muscle strength. This relation can be explained by arthrogenic muscle inhibition, which is referred to as the decrease in the efferent motor neuron stimulation in the skeletal muscle, by the changes in the afferent component of the involved joint. Kemnitz et al. showed that knee and hip pain in patients with osteoarthritis causes a decrease in the muscle strength and quality in the lower extremities and therefore results in an increased risk of falls; they also reported that disability is not related to the degree of radiographic

Table 3. The different parameters between with moderate sarcopenia and non-sarcopenic

| Sarcopenia                  | Average | Median | Standard deviation | Minimum | Maximum | p     |
|----------------------------|---------|--------|--------------------|---------|---------|-------|
| Amylase (25–90 u/l)         |         |        |                    |         |         |       |
| Middle                     | 72.1    | 71.5   | 21.5               | 35      | 100     | 0.013 |
| No                         | 61.1    | 55     | 28.2               | 18      | 172     |       |
| Iron (50–170 ug/dL)         |         |        |                    |         |         |       |
| Middle                     | 77.9    | 70.5   | 31.3               | 21      | 144     | 0.028 |
| No                         | 61.7    | 59     | 22.6               | 16      | 117     |       |
| Potassium (3.5–5.4 mEq/L)   |         |        |                    |         |         |       |
| Middle                     | 4.4     | 4.4    | 0.5                | 3.6     | 5.7     | 0.007 |
| No                         | 4.7     | 4.6    | 0.6                | 2.4     | 5.9     |       |
| Protein (6.4–8.3 g/l)       |         |        |                    |         |         |       |
| Middle                     | 7.4     | 7.6    | 0.9                | 4.2     | 8.5     | 0.043 |
| No                         | 7.1     | 7.3    | 0.9                | 4.2     | 9.1     |       |
| Sedimentation (<20 mm/hour) |         |        |                    |         |         |       |
| Middle                     | 17.1    | 9.5    | 14.1               | 4       | 45      | <0.05 |
| No                         | 34.6    | 35     | 20.4               | 4       | 80      |       |
| Hemoglobin (12–15.5 g/dl)   |         |        |                    |         |         |       |
| Middle                     | 13.5    | 13.5   | 1.2                | 10.9    | 16.2    | <0.05 |
| No                         | 12.3    | 12.3   | 1.5                | 7.5     | 16.2    |       |
| Hand Dynamometer (kg)       |         |        |                    |         |         |       |
| Middle                     | 33.1    | 35     | 11.1               | 12      | 56      | <0.05 |
| No                         | 19.8    | 18     | 7.8                | 4       | 46      |       |
| Height (kg)                 |         |        |                    |         |         |       |
| Middle                     | 167.5   | 167.5  | 5.05               | 157     | 177     | <0.05 |
| No                         | 155.4   | 155    | 8.1                | 141     | 175     |       |
| Muscle mass (kg)            |         |        |                    |         |         |       |
| Middle                     | 56.1    | 53.7   | 5.2                | 40.1    | 64.2    | <0.05 |
| No                         | 45.9    | 44.7   | 7.8                | 29.3    | 70.5    |       |
| BMI (kg/m²)*                |         |        |                    |         |         |       |
| Middle                     | 28      | 27.9   | 4.6                | 20.4    | 38.3    | <0.05 |
| No                         | 32.4    | 32.1   | 5.5                | 18.7    | 49.4    |       |

*BMI (kg/m²): Body mass index.
In a study conducted on Quadriceps muscle plays an important role in The present study showed that the presence of osteoarthritis and lower extremity weakness and found a relationship between quadriceps muscle weakness and osteoarthritis. The same study also found quadriceps muscle weakness commonly associated with knee osteoarthritis and lower extremity weakness and found a relationship between quadriceps muscle weakness and osteoarthritis in the absence of knee pain or muscle atrophy and this was explained by the presence of muscle function. Quadriceps muscle weakness was defined as the primary risk factor for the progression of joint destruction in patients with knee osteoarthritis. A similar study conducted on in-patients reported a relationship between quadriceps muscle weakness and being confined to bed and a similar relationship has been proposed for other people in the community.

In the present study, patients with osteoarthritis had lower muscle strength. The study group in this study was composed of patients with knee osteoarthritis. Thus, we did not expect that handgrip strength measuring with hand dynamometer would be affected; however, handgrip strength showing the muscle strength was lower (19.5) in patients with osteoarthritis. This raises the possibility that there might a decrease in overall muscle strength and not only in the muscles around the involved joints. In a study reporting on males with hip osteoarthritis, muscle strength in the adductor, abductor and flexor muscles of the hip joint were found to be lower in patients with osteoarthritis. Another study conducted on patients with and without knee pain showed a relationship between quadriceps muscle strength and activation and knee pain. The get-up and go test evaluated the muscle performance, which is a component of sarcopenia. Quadriceps muscle plays an important role in climbing up the stairs, walking and standing, and weakness in this muscle directly causes loss of function in the patients. In the present study, patients with osteoarthritis achieved poorer scores in the get-up and go test compared to those without osteoarthritis. Waters et al. found significantly lower walking speed in patients with osteoarthritis than in those without osteoarthritis. Another study showed limitation in the activities in subjects with knee pain. Same study also showed a relationship between quadriceps muscle weakness and disability in patients with knee pain.

The rates of patients with a mid-upper arm circumference lower than 20 cm and a calf circumference lower than 31 cm were higher among patients with osteoarthritis. These anthropometric measurements can be regarded as indirect indications of sarcopenia. Total protein, albumin, complete blood count, and magnesium levels were lower in patients with osteoarthritis. This can be regarded as the reflection of inflammatory process related to osteoarthritis.

**Conclusion**

There was a significant association between osteoarthritis and sarcopenia in geriatric patients with type 2 diabetes mellitus. The association between osteoarthritis and sarcopenia could be mediated by functional and cellular pathways. The authors consider that osteoarthritis results in sarcopenia by causing immobility and a decrease in functional performance. Clinical implication of these findings would be that physicians should be aware of increased risk of sarcopenia in patients with osteoarthritis. Detection of sarcopenia in such patients is particular importance for developing therapeutic and preventive strategies.

It is currently difficult to answer the causality dilemma of which came first, osteoarthritis, or sarcopenia?
Disclosures
Ethics Committee Approval: The Ethics Committee of University of Health Sciences Umraniye Education and Research Hospital, Date: 22.01.2016; Number: 1154.

Peer-review: Externally peer-reviewed.

Conflict of Interest: None declared.

Authorship Contributions: Concept – S.B, R.S.; Design – S.B, R.S.; Supervision – S.B.; Materials – R.S., D.O., E.S.; Data collection &/or processing – R.S., D.O., E.S., A.B; Analysis and/or interpretation – S.B., A.B; Literature search – R.S., D.O., E.S., S.A.; Writing – R.S., S.A.; Critical review – S.B.

References
1. Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, et al. Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish diabetes epidemiology study (TURDEP). Diabetes Care 2002;25:1551–6.
2. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 yr. Diabetes 1987;36:523–34.
3. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:3–19.
4. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998;81:18B–25B.
5. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996;97:2509–16.
6. Milte R, Crotty M. Musculoskeletal health, frailty and functional decline. Best Pract Res Clin Rheumatol 2014;28:395–410.
7. Fried LP, Guralnik JM. Disability in older adults: evidence regarding significance, etiology, and risk. J Am Geriatr Soc 1997;45:92–100.
8. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc 2004;52:80–5.
9. Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 2010;29:154–9.
10. Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci 2000;55:M716–24.
11. Karasik D, Kiel DP. Evidence for pleiotropic factors in genetics of the musculoskeletal system. Bone 2010;46:1226–37.
12. Toda Y, Segal N, Toda T, Kato A, Toda F. A decline in lower extremity lean body mass per body weight is characteristic of women with early phase osteoarthritis of the knee. J Rheumatol 2000;27:2449–54.
13. Cho HJ, Chang CB, Kim KW, Park JH, Yoo JH, Koh UJ, et al. Gender and prevalence of knee osteoarthritis types in elderly Koreans. J Arthroplasty 2011;26:994–9.
14. Sönmez MM, Berk A,UGHurlar M, Ertürer RE, Akman Ş, Öztürk I. Midterm clinical and radiological outcomes of total knee arthroplasty. Sisli Etfal Hastan Tip Bul 2016;50:115–23.
15. Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 2005;289:E735–45.
16. Rubenstein LZ, Harker JO, Salvà A, Guigoz Y, Vellas B. Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF). J Gerontol A Biol Sci Med Sci 2001;56:M366–72.
17. Altman RD, Hochberg M, Murphy WA Jr, Wolfe F, Lequesne M. Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage 1995;3 Suppl A:3–70.
18. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthritis. Ann Rheum Dis 1957;16:494–502.
19. Cesari M, Leeuwenburgh C, Lauretani F, Onder G, Bandinelli S, Maraldi C, et al. Frailty syndrome and skeletal muscle: results from the Invecchiare in Chianti study. Am J Clin Nutr 2006;83:1142–8.
20. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002;50:889–96.
21. Schmidt RT, Toews JV. Grip strength as measured by the Jamar dynamometer. Arch Phys Med Rehabil 1970;51:321–7.
22. Mathias S, Nayak US, Isaacs B. Balance in elderly patients: the ”get-up and go” test. Arch Phys Med Rehabil 1986;67:387–9.
23. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M; Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN). ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003;22:415–21.
24. Roubenoff R. Origins and clinical relevance of sarcopenia. Can J Appl Physiol 2001;26:78–89.
25. Cruz-Jentoft AJ, Landi F, Topinková E, Michel JP. Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care 2010;13:1–7.
26. Cruz-Jentoft AJ, Landi F, Schneider SM, Zühiga C, Arai H, Boirie Y, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014;43:748–59.
27. Joseph C, Kenny AM, Taxel P, Lorenzo JA, Duque G, Kuchel GA. Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk. Mol Aspects Med 2005;26:181–201.
28. Kellgren JH, Lawrence JS. Osteo-arthritis and disk degeneration in an urban population. Ann Rheum Dis 1958;17:388–97.
29. Ekdahl C, Andersson SI, Svensson B. Muscle function of the lower extremities in rheumatoid arthritis and osteoarthritis. A descriptive study of patients in a primary health care district. J Clin Epidemiol 1989;42:947–54.
30. Norman K, Pichard C, Lochs H, Pirlich M. Prognostic impact of...
disease-related malnutrition. Clin Nutr 2008;27:5–15.
31. Arokoski MH, Arokoski JP, Haara M, Kankaanpää M, Vesterinen M, Niemitukia LH, et al. Hip muscle strength and muscle cross sectional area in men with and without hip osteoarthritis. J Rheumatol 2002;29:2185–95.
32. Zhai G, Blizzard L, Srikanth V, Ding C, Cooley H, Cicuttini F, et al. Correlates of knee pain in older adults: Tasmanian Older Adult Cohort Study. Arthritis Rheum 2006;55:264–71.
33. Slemenda C, Brandt KD, Heilman DK, Mazzuca S, Braunstein EM, Katz BP, et al. Quadriceps weakness and osteoarthritis of the knee. Ann Intern Med 1997;127:97–104.
34. Kemnitz J, Wirth W, Eckstein F, Ruhdorfer A, Culvenor AG. Longitudinal change in thigh muscle strength prior to and concurrent with symptomatic and radiographic knee osteoarthritis progression: data from the Osteoarthritis Initiative. Osteoarthritis Cartilage 2017;25:1633–40.
35. Kemmler W, Teschler M, Goisser S, Bebenek M, von Stengel S, Bollheimer LC, et al. Prevalence of sarcopenia in Germany and the corresponding effect of osteoarthritis in females 70 years and older living in the community: results of the FORMoSA study. Clin Interv Aging 2015;10:1565–73.
36. Young A, Stokes M, Crowe M. The size and strength of the quadriceps muscles of old and young men. Clin Physiol 1985;5:145–54.
37. McAlindon TE, Cooper C, Kirwan JR, Dieppe PA. Determinants of disability in osteoarthritis of the knee. Ann Rheum Dis 1993;52:258–62.
38. O'Reilly SC, Jones A, Muir KR, Doherty M. Quadriceps weakness in knee osteoarthritis: the effect on pain and disability. Ann Rheum Dis 1998;57:588–94.
39. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412–23.
40. Waters RL, Perry J, Conaty P, Lunsford B, O'Meara P. The energy cost of walking with arthritis of the hip and knee. Clin Orthop Relat Res 1987;278–84.